Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Neoplasms 4Breast Neoplasms 4Neoplasm Metastasis 3Lung Neoplasms 3Triple Negative Breast Neoplasms 2Multiple Myeloma 2Lymphoma 2Glioblastoma 2Colorectal Neoplasms 2Stroke 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neurologic Manifestations 1Myelodysplastic Syndromes 1Motor Activity 1Melanoma 1Margins of Excision 1Malignant Solid Neoplasm 1Malignant Female Reproductive System Neoplasm 1Localized Head and Neck Carcinoma 1Leukemia, Myeloid, Acute 1Leukemia 1Inflammatory Breast Neoplasms 1Hematologic Neoplasms 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Depression 1Communication 1

Interventions

pembrolizumab 44Carboplatin 35Paclitaxel 27Specimen Handling 18Cyclophosphamide 16Capecitabine 16Magnetic Resonance Spectroscopy 14sacituzumab govitecan 13Gemcitabine 13Taxes 12Biopsy 12130-nm albumin-bound paclitaxel 11Albumin-Bound Paclitaxel 9Doxorubicin 8olaparib 7Nivolumab 7fludarabine 6Cisplatin 6eribulin 5atezolizumab 5Radiotherapy 5Docetaxel 5durvalumab 4Fulvestrant 4Epirubicin 4Bevacizumab 4veliparib 3famitinib 3abemaciclib 3Vinorelbine 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Palliative Care × 90 days × Clear all
NCT07510802 2026-04-06

Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

Beijing Biotech

Phase 1/2 Recruiting
60 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT07486089 2026-03-20

DUAL-NK-BC

Beijing Biotech

Phase 1/2 Recruiting
60 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡